Gritstone bio shares are trading higher after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a next-generation vaccine candidate for COVID-19 valued at up to $433 million.
Portfolio Pulse from Benzinga Newsdesk
Gritstone bio has been awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a next-generation vaccine candidate for COVID-19. The contract is valued at up to $433 million, which has led to an increase in the company's share price.
September 27, 2023 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gritstone bio's stock price is likely to increase in the short term due to the announcement of a significant BARDA contract for a COVID-19 vaccine study.
The announcement of a significant contract for a COVID-19 vaccine study is a positive development for Gritstone bio. This news is likely to increase investor confidence in the company, leading to an increase in demand for the company's shares and, consequently, an increase in the share price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100